Latest filing published 29 Jan 2026 for REGENXBIO Inc., €2.5M. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Kenneth T. Mills in REGENXBIO Inc., where the filings describe the role as chief executive. Between 13 June 2016 and 27 January 2026, the trades on record add up to 125 filings.
The open-market record consists of 86 sales worth €17.4M, with no purchase. Other entries cover 4 share grants and 34 option exercises.
The newest entry dates from 29 January 2026: an option exercise of €2.5M, in REGENXBIO Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
21 of 21 declarations